ISRCTN71318684 https://doi.org/10.1186/ISRCTN71318684

UKCCCR Randomised Trial of Adjuvant Hormone Therapy (AHT) in Ovarian Cancer

Submission date 19/08/2002	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 19/08/2002	**Overall study status** Completed	
Last Edited 24/10/2019	**Condition category** Cancer	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr - -

Contact details
UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
United Kingdom
NW1 2DA

Additional identifiers

Protocol serial number
ICR/AHT

Study information

Scientific Title
UKCCCR Randomised Trial of Adjuvant Hormone Therapy (AHT) in Ovarian Cancer

Study objectives
Not provided at time of registration

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Study type(s)
Treatment

Health condition(s) or problem(s) studied
Ovarian cancer

Interventions
1. AHT Regimen: Adjuvant hormone therapy (AHT), type according to the preference of the patient's consultant, providing the prescribing practice is consistent. It is recommended that premenopausal women receive higher doses than peri- and postmenopausal women. Treatment to begin within 2 weeks of randomisation. AHT to be prescribed for a minimum of 5 years if tolerated.

2. Control Regimen: No treatment with AHT.

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Hormone therapy

Primary outcome(s)
Not provided at time of registration

Key secondary outcome(s))
Not provided at time of registration

Completion date
30/11/1995

Eligibility

Key inclusion criteria
1. Histologically confirmed epithelial ovarian cancer diagnosed within the last 9 months
2. Pre and/or postmenopausal

3. Chemotherapy and radiotherapy may be given at the discretion of the participating clinician, provided it does not include hormonal treatment other than that allocated in the trial
4. No history of hormone dependent malignancy
5. No contraindications to AHT

Participant type(s)
Patient

Healthy volunteers allowed
No

Age group
Not Specified

Sex
Female

Key exclusion criteria
Patients for whom ovarian function has been deliberately preserved are excluded

Date of first enrolment
01/01/1990

Date of final enrolment
30/11/1995

Locations

Countries of recruitment
United Kingdom

England

Study participating centre
MRC Clinical Trials Unit
London
United Kingdom
NW1 2DA

Sponsor information

Organisation
UK Co-ordinating Committee for Cancer Research (UKCCCR)

ROR

https://ror.org/054225q67

Funder(s)

Funder type
Research organisation

Funder Name
Cancer organisations (UK)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	10/12/2015	24/10/2019	Yes	No